ARTICLE / CLIENT ALERT
CMS Dramatically Modifies and Expedites the Medicare Enrollment Process to Combat COVID-19
March 23, 2020
Read time: 7 min
The Centers for Medicare and Medicaid Services is expediting Medicare enrollment applications and allowing certain categories of practitioners to temporarily enroll in Medicare Part B to increase the number of healthcare workers available to diagnose and treat patients with Coronavirus (COVID-19). To obtain temporary billing privileges, physicians and non-physician practitioners should contact their Medicare Administrative Contractor using the telephone hotline numbers established for these purposes.
In response to the spread of Coronavirus (COVID-19), the Centers for Medicare and Medicaid Services (CMS) has waived certain Medicare and Medicaid program requirements under the authority granted to CMS by Section 1135 of the Social Security Act. This authority was triggered by the president’s declaration of a national emergency under the National Emergencies Act, and the Health and Human Services Secretary’s declaration of a public health emergency under the Public Health Service Act. For more information, see McDermott’s On the Subject “Section 1135 Waivers Now Available, But Some Waivers May Require Approval”.
Pursuant to its authority, CMS issued several “blanket” Section 1135 waivers that are available to providers and suppliers in relation to the COVID-19 pandemic. One such blanket waiver allows non-certified Part B physicians and non-physician practitioners to enroll and receive temporary Medicare billing privileges in order to increase the numbers of healthcare workers available to diagnose and treat patients with COVID-19. CMS waived the application fee, fingerprint-based criminal background checks, and site visits that are typically part of the screening requirements during the enrollment process. Through this waiver, CMS also postponed all revalidations and is allowing licensed providers to render services outside of their state of enrollment. Any pending or new applications will be processed on an expedited timeline.
The opportunity to temporarily enroll in Medicare Part B is extended only to physicians and non-physician practitioners. All other suppliers, including suppliers of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS), are required to submit initial enrollments and changes of information via the appropriate CMS-855 application. Applications received on or after March 1, 2020, will be processed on an expedited timeline, and CMS has waived the application fee, criminal background checks and site visits for these applications.
Eligible physicians and non-physician practitioners seeking to temporarily enroll in Medicare Part B, either for the first time or at a new practice location, including a home address for services furnished remotely or via telehealth, can do so over the phone by contacting the Medicare Administrative Contractor (MAC) that is associated with their state of enrollment. To enroll, physicians or practitioners generally need the following information, depending on the provider/entity type:
Group MemberPhysician AssistantSole ProprietorOrganization
| Group Member | Physician Assistant | Sole Proprietor | Organization |
|
|
|
|
The MAC will attempt to screen and enroll the physician or non-physician practitioner over the phone, and will notify the physician or non-physician practitioner of approval or rejection of temporary Medicare billing privileges during the phone conversation. Applicants who are excluded from Medicare and other healthcare programs by the Office of Inspector General will be rejected. Applicants with a current adverse action on their license must wait at least 24 hours for CMS and the MAC to determine whether billing privileges will be granted. Approved applicants will receive a PTAN/billing number and a retroactive billing effective date that may be as early as March 1, 2020. The MAC will also send the provider a temporary billing approval letter.
Physicians and non-physician practitioners seeking to temporarily enroll in Medicare or to report a change in practice location pursuant to the Section 1135 waiver should contact their jurisdictional MAC at the phone numbers below, Monday through Friday. These hotlines should also be used by any physicians, practitioners or other suppliers who have questions regarding the other provider enrollment flexibilities afforded by the Section 1135 waiver. These hotlines will be operational until the public health emergency declaration is lifted.
| Jurisdiction | MAC | States/Territories | Contact Information |
| 5 | WPS | IA, KS, MO, NE | +1 844 209 2567 7 am – 4 pm CDT |
| 6 | NGS | IL, MN, WI | + 1 888 802 3898 8 am – 4 pm CDT |
| 8 | WPS | IN, MI | +1 844 209 2567 7 am – 4 pm CDT |
| 15 | CGS | KY, OH | +1 855 769 9920 7 am – 4 pm CDT |
| E | Noridian | CA, HI, NV, American Samoa, Guam, Northern Mariana Islands | +1 866 575 4067 8 am – 6 pm CDT |
| F | Noridian | AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY |
+1 866 575 4067 8 am – 6 pm CDT |
| H | Novitas | AR, CO, LA, MS, NM, OK, TX |
+1 855 247 8428 8:30 am – 4 pm EDT |
| J | Palmetto | AL, GA, TN | +1 833 820 6138 8:30 am – 5 pm EDT |
| K | NGS | CT, ME, MA, NH, NY, RI, VT |
+1 888 802 3898 8 am – 4 pm CDT |
| L | Novitas | DE, MD, NJ, PA, DC | +1 855 247 8428 8:30 am – 4 pm EDT |
| M | Palmetto | NC, SC, VA, WV | +1 833 820 6138 8:30 am – 5 pm EDT |
| N | FCSO | FL, Puerto Rico, US Virgin Islands | +1 855 247 8428 8:30 am – 4 pm EDT |
| A (DME) | Noridian | CT, DE, DC, ME, MD, MA, NH, NJ, NY, PA, RI, VT |
+1 866 575 4067 8 am – 6 pm CDT |
| B (DME) | CGS | IL, IN, KY, MI, MN, OH, WI |
+1 855 769 9920 7 am – 4 pm CDT |
| C (DME) | CGS | AL, AR, CO, FL, GA, LA, MS, NM, NC, OK, SC, TN, TX, VA, WV, Puerto Rico, US Virgin Islands |
+1 855 769 9920 7 am – 4 pm CDT |
| D (DME) | Noridian | AK, AZ, CA, HI, ID, IA, KS, MO, MT, NE, NV, ND, OR, SD, UT, WA, WY, American Samoa, Guam, Northern Mariana Islands |
+1 866 575 4067 8 am – 6 pm CDT |
The MACs will deactivate the temporary PTANs when the president declares that the national emergency is over. Providers seeking to fully enroll with the applicable MAC must submit a complete application, which the MAC will expedite.
Key Takeaways
Medicare will only make payments to providers and suppliers that are enrolled in Medicare Part B at the location where they provide services. In response to the challenges of providing care during the COVID-19 national emergency, CMS exercised its authority to allow temporary enrollment in Medicare Part B for certain categories of physicians and non-physician practitioners, and to expedite enrollment for other providers and suppliers. Individuals and entities seeking temporary enrollment, including of temporary practice locations such as a physician or non-physician practitioner’s home, should contact their MAC at the numbers listed above. Failure to seek temporary enrollment may result in rejected claims, delays in payment or inability to receive payment for services furnished to Medicare beneficiaries.

Employers Can Immediately Recover the Cost of Mandatory COVID-19-Related Leave Through Reducing Payroll Taxes
ARTICLE / CLIENT ALERT
Employers Can Immediately Recover the Cost of Mandatory COVID-19-Related Leave Through Reducing Payroll Taxes
March 23, 2020
Read time: 4 min
The Families First Coronavirus Response Act requires employers with less than 500 employees to provide 10 days paid sick leave plus paid FMLA leave for COVID-19-related reasons. We outline the ways employers can immediately take advantage of this change.
The Families First Coronavirus Response Act (the “Act”) requires employers with less than 500 employees to provide 10 days paid sick leave plus paid FMLA leave for COVID-19-related reasons. See additional details regarding sick leave and child leave required under the Act.
Critically, the Act provides tax credits for the employer portion of Social Security and Medicare taxes. These credits are effective for statutory benefits paid starting on a date not later than April 2, 2020 (to be designated by Treasury), and ending on December 31, 2020.
Employers can take advantage of this change immediately. Employers can retain payroll taxes equal to the amount of qualifying sick and child care leave that is paid under the Act, rather than deposit it with the IRS. Although the tax credits provided under the Act are for the employer portion of Social Security and Medicare taxes, for purposes of administering or retaining the tax credits, the IRS announced on Friday, March 20, that payroll taxes for this purpose include federal income tax withholding amounts (FITW), the employee share of Social Security and Medicare taxes, and the employer share of Social Security and Medicare taxes with respect to all employees.
If there are not sufficient payroll taxes to cover the cost of statutory benefits paid, employers will be able to file a request for an accelerated payment from the IRS. The IRS has announced that it will process these requests in two weeks or less. Details on how to claim these credits are expected later this week.
Now, for more details, let’s look at each statutory benefit and how tax credits will work for each.
Paid Sick Leave Tax Credit
The paid sick leave tax credit applies to the employee’s regular rate of pay subject to limits that vary depending upon the type of leave as follows:
- If an employee qualifies for sick pay leave due to (i) being unable to work because of a COVID- 19 quarantine or self-quarantine or (ii) having COVID-19 symptoms and seeking a medical diagnosis, the tax credit equals 100% of the employee’s regular rate of pay up to a cap of $511 per day (which is a cap of $5,110 in the aggregate if the employee takes the maximum 10 days of paid sick leave).
- If an employee is (i) caring for someone with COVID-19, or caring for a child because the child’s school or child care facility is closed or (ii) caring for a child because the child care provider is unavailable due to COVID-19, the tax credit is two-thirds of the employee’s regular rate of pay up to a cap of $200 per day (which is a cap of $2,000 in the aggregate if the employee takes the maximum 10 days of paid sick leave).
In either case, an additional tax credit will also be available for certain costs to maintain health insurance coverage for these employees on a covered leave. Guidance from Treasury is expected later this week to address how this will work.
Child Care Leave Credit
An employee may take FMLA leave due to being unable to work because of a need to care for a child whose school or child care facility is closed or whose child care provider is unavailable due to COVID-19. Employees may take 12 weeks of leave for this purpose, with the initial two weeks unpaid and the remaining 10 weeks paid at two-thirds their regular rate of pay.
The amount of the child care tax credit is equal to two-thirds of the employee’s regular pay, capped at $200 per day or $10,000 in the aggregate (if the full 10 weeks of paid FMLA leave is taken). An additional tax credit for certain costs to maintain health insurance coverage during a covered child care leave will also be available.
For more information on COVID-19, please consult your regular McDermott Employment and Employee Benefit lawyers and our continually updated Coronavirus Resource Center.

OCR Enforcement Waivers of Certain HIPAA Requirements in Furtherance of Telehealth During COVID-19 Pandemic
ARTICLE / CLIENT ALERT
OCR Enforcement Waivers of Certain HIPAA Requirements in Furtherance of Telehealth During COVID-19 Pandemic
March 23, 2020
Read time: 20 min
In response to the global Coronavirus (COVID-19) pandemic, US state and federal government agencies have worked to promote utilization of telehealth. Prior to and following President Trump’s declaration of a national emergency related to the COVID-19 pandemic, the HHS Office for Civil Rights has issued bulletins and guidance to help ensure that the provision of telehealth and other services is not inappropriately constrained during the pandemic by HIPAA privacy and security requirements. This On the Subject summarizes key insights, open questions and operational tips related to OCR’s COVID-19 related guidance and opportunities for additional OCR guidance.
In response to the global Coronavirus (COVID-19) pandemic, US state and federal government agencies have worked to promote utilization of telehealth. On March 13, 2020, President Trump issued a Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (the Presidential Proclamation Concerning COVID-19), providing that the Secretary of the US Department of Health and Human Services (HHS) may exercise authority to temporarily waive or modify certain requirements of the Medicare, Medicaid, and state Children’s Health Insurance programs and the Health Insurance Portability and Accountability Act (HIPAA).
To that end, the Centers for Medicare and Medicaid Services (CMS) have expanded Medicare’s telehealth benefits. Myriad state and federal government agencies, government payors and private payors have expanded reimbursement for telehealth services and loosened professional licensure restrictions to promote implementation. The HHS Office for Civil Rights (OCR) has issued the following bulletins and guidance (collectively, the OCR COVID-19 Guidance) to help ensure that the provision of telehealth and other services during the COVID-19 pandemic is not inappropriately constrained by HIPAA privacy and security requirements:
- OCR, FAQs on Telehealth and HIPAA during the COVID-19 nationwide public health emergency, March 20, 2020 (OCR FAQs 3/20/20)
- OCR, Notification of Enforcement Discretion for telehealth remote communications during the COVID-19 nationwide public health emergency, March 17, 2020 (OCR Notification 3/17/20)
- OCR, Bulletin: Limited Waiver of HIPAA Sanctions and Penalties During a Nationwide Public Health Emergency, March 16, 2020 (OCR Bulletin 3/16/20)
- OCR, Bulletin: HIPAA Privacy and Novel Coronavirus, February 3, 2020 (OCR Bulletin 2/3/20)
This On the Subject summarizes key insights, open questions and operational tips related to the OCR COVID-19 Guidance and opportunities for additional OCR guidance.
Privacy and Security Compliance Insights and Open Questions
- OCR will not impose penalties for noncompliance with HIPAA against covered entity healthcare providers in connection with the good faith provision of telehealth during the COVID-19 national emergency. Covered entity healthcare providers that want to use remote communication technologies to provide telehealth to patients during the COVID-19 national emergency—even if the telehealth is not related to the diagnosis or treatment of COVID-19—can use any “non-public facing” remote communication products that are available to communicate with patients.
Non-public facing remote communication products would include, for example, in the video application context, Apple FaceTime, Facebook Messenger video chat, Google Hangouts video, Whatsapp video chat and Skype, and, in the text application context, Signal, Jabber, Facebook Messenger, Google Hangouts, Whatsapp and iMessage.
In OCR Notification 3/17/20, OCR states that, effective immediately, OCR will exercise its enforcement discretion and will not impose penalties for noncompliance with HIPAA against covered entity healthcare providers in connection with the good faith provision of telehealth during the COVID-19 national emergency. OCR specifically states that covered entity healthcare providers that want to use remote communication technologies to provide telehealth to patients during the COVID-19 national emergency—even if the telehealth is not related to the diagnosis or treatment of COVID-19—can use any “non-public facing” remote audio or video communication products that are available—e.g., Apple FaceTime, Facebook Messenger video chat, Google Hangouts video or Skype—to communicate with patients.
This list of remote communication product examples provided in OCR Notification 3/17/20 was not intended to be exhaustive. In the OCR FAQs 3/20/20, OCR provided additional examples of remote communication products to which the enforcement waiver would apply and clarified that they could include text applications and not just audio and video applications. The list was expanded to include, for video applications, WhatsApp video chat, and, for text applications, Signal, Jabber, Facebook Messenger, Google Hangouts, Whatsapp and iMessage. In the OCR FAQs 3/20/20, OCR notes favorably that these applications typically employ end-to-end encryption, support individual user accounts, logins and passcodes to help limit access and verify participants, and/or permit participants to assert some degree of control of particular capabilities, such as choosing to record or not record the communication or to mute or turn off the video or audio at any point.
OCR acknowledges in OCR Notification 3/17/20 that the enforcement waiver extends to failures to enter into business associate agreements with vendors of such non-public facing remote communication products and utilization of non-HIPAA-compliant remote communication products. However, OCR distinguishes the above “non-public facing” remote communication products from “public facing” remote communication products—e.g., Facebook Live, Twitch, TikTok and similar video communication applications—which are not subject to the enforcement waiver and may not be used in the provision of telehealth. OCR notes in the OCR FAQs 3/20/20 that these products are designed to be open to the public or allow wide or indiscriminate access to the communication and, accordingly, a provider that chooses to use such products would not be covered by the enforcement waiver.
The enforcement waiver extends only to covered entities that are healthcare providers and not to covered entities that are health plans or healthcare clearinghouses. OCR made clear in the OCR FAQs 3/20/20 that even health plans that pay for telehealth services are not subject to the enforcement waiver because they are not engaged in the provision of healthcare.
- OCR encourages providers to notify patients that third-party communications applications potentially introduce privacy risks and to enable all available encryption and privacy modes when using such applications.
In OCR Notification 3/17/20, OCR encourages covered entity healthcare providers to notify patients that remote communication products potentially introduce privacy risks and to enable all available encryption and privacy modes when using such products. OCR does not address whether the patient notifications of privacy risks should be in writing and provided prior to a telehealth visit or whether they may be provided orally at the beginning of a telehealth visit. Because OCR is merely “encouraging” and not “requiring” providers to provide such notifications, providers will need to evaluate the feasibility of such notifications and the most appropriate methods of implementation.
- OCR advises that covered entity healthcare providers that seek additional privacy protections for telehealth should provide such services using vendors that provide HIPAA-compliant remote communication products and that will enter into business associate agreements in connection with the provision of their products.
While exercising its enforcement discretion as to utilization of non-HIPAA-compliant communication products by covered entity health-care providers for telehealth in connection with the good faith provision of telehealth during the COVID-19 national emergency, OCR also advises that covered healthcare providers that seek additional privacy protections for telehealth should provide such services using vendors that provide HIPAA-compliant remote communication products and that will enter into business associate agreements in connection with the provision of their products. In OCR Notification 3/17/20, OCR provides a non-exhaustive list of vendors that represent that they provide HIPAA-compliant video communication products and will enter into business associate agreements, e.g., Skype for Business, Updox, VSee, Zoom for Healthcare, Doxy.me, and Google G Suite Hangouts Meet. Because OCR is merely advising providers that seek additional privacy protection to utilize such vendors (and not requiring providers to use such vendors), providers will need to evaluate the feasibility of engaging such vendors during the national emergency.
When the national emergency and enforcement waiver described in OCR Notification 3/17/20 terminate—and perhaps even in anticipation of eventual termination—providers that are not utilizing “HIPAA-compliant” remote communication products as described in the OCR COVID-19 Guidance will need to evaluate, inter alia, whether their preferred product vendors are appropriately characterized as “business associates” or as mere “conduits” (in accordance with existing OCR guidance, which distinction is beyond the scope of this article) and/or whether they should transition to “HIPAA-compliant” products and vendors as described in the OCR COVID-19 Guidance.
- The enforcement waiver described in OCR Notification 3/17/20 does not have an expiration date. OCR will issue an additional notice to the public when it is no longer exercising its enforcement discretion based on then-present facts and circumstances.
The enforcement waiver described in OCR Notification 3/17/20 does not contain a specific expiration date. Because OCR Notification 3/17/20 states that OCR will not impose penalties for noncompliance in connection with the good faith provision of telehealth “during the COVID-19 nationwide public health emergency,” one might conclude that the enforcement waiver would automatically terminate upon a presidential proclamation that the national emergency declared in the Presidential Proclamation Concerning COVID-19 has terminated. However, OCR has clarified in the OCR FAQs 3/20/20 that the enforcement waiver would terminate only after OCR issues an additional notice to the public that it is no longer exercising its enforcement discretion based on then-present facts and circumstances. Consequently, the enforcement waiver described in OCR Notification 3/17/20 might theoretically be terminated before or after the national emergency declared in the Presidential Proclamation Concerning COVID-19 has terminated.
- The enforcement waiver described in the OCR COVID-19 Guidance may not extend to non-HIPAA-compliant voicemail applications. Providers should further evaluate utilization of such applications prior to implementation.
The OCR COVID-19 Guidance makes clear that the enforcement waiver extends to non-public facing remote communication products with specific reference to audio, video and text applications. The OCR COVID-19 Guidance does not specifically address voicemail applications. OCR notes in the OCR FAQs 3/20/20 that the products to which it has specifically extended its enforcement waiver typically employ end-to-end encryption, support individual user accounts, logins and passcodes to help limit access and verify participants, and/or permit participants to assert some degree of control of particular capabilities, such as choosing to record or not record the communication or to mute or turn off the video or audio at any point. Voicemail is by its nature a recorded communication, and one of the products listed by OCR states on its website that voice messages are encrypted when they are delivered to the user, but, after the user listens to the message, the voicemail is transferred from the vendor’s servers to the user’s local device where it is stored as an unencrypted file. Because voicemail is not specifically addressed by the OCR COVID-19 Guidance, providers should further evaluate utilization of non-HIPAA-compliance voicemail applications prior to implementation.
- Covered entity healthcare providers may want to consider including non-public facing remote communication products in the scope of their HIPAA security rule risk analyses.
As described above, the OCR COVID-19 Guidance states that OCR will not impose penalties against covered entity healthcare providers for non-compliance with HIPAA requirements in connection with the good faith provision of telehealth services during the COVID-19 nationwide public health emergency. To that end, OCR specifically acknowledges in OCR Notification 3/17/20 that the enforcement waiver extends to failures to enter into business associate agreements with vendors of certain non-public facing remote communication products and utilization of certain non-HIPAA-compliant remote communication products. OCR also makes clear in the OCR FAQs 3/20/20 that it will not impose penalties if electronic PHI (EPHI) is intercepted during transmission while the provider is using one of the non-public facing remote communication products that it describes.
However, OCR does not specifically address whether covered entity healthcare providers must nonetheless include such non-public facing remote communication products within the scope of their HIPAA Security Rule risk analyses and is silent on whether OCR will impose penalties against covered entity healthcare providers for failure to do so. Inclusion of such products within the scope of security risk analyses would ordinarily be required under the HIPAA Security Rule.
Conducting a security risk analysis is primarily an “internal” process for covered entity healthcare providers. A security risk analysis could be completed by the covered entity healthcare provider in the absence of any affirmative act by the remote communication product vendor and irrespective of the compliance status of the remote communication product or vendor. Because conducting a security risk analysis is different in that respect (i.e., it is primarily an internal process) from executing a business associate agreement with an external remote communication product provider, and because OCR is silent on whether OCR will impose penalties against covered entity healthcare providers for failure to include such products in their security risk analysis, covered entity healthcare providers should consider, notwithstanding the OCR COVID-19 Guidance, including non-public facing remote communication products in the scope of their security risk analyses, with specific consideration of:
- Identifying and documenting reasonably anticipated threats to the confidentiality, availability and integrity of EPHI processed by the product.
- Assessing and documenting the technical, physical and administrative security measures used to safeguard EPHI transmitted through the product, whether security measures required by the Security Rule are already in place and configured and used property.
- Assessing the likelihood of potential risks and threat occurrences to EPHI.
- Assessing the impact of potential risks to the confidentiality, integrity and availability of EPHI (i.e., the qualitative and/or quantitative magnitude of the potential impact resulting from a threat triggering or exploiting a specific vulnerability).
- Assigning risk levels for all threat vulnerability combinations identified during the risk analysis based on the likelihood of threat occurrence and resulting impact/magnitude.
- Identifying and documenting corrective actions (e.g., new or amended security procedures) to reduce all identified risks to a reasonable and appropriate level. (For example, if the product presents a risk of unplanned downtime during regular patient care hours, the covered entity may wish to reduce that risk by identifying a back-up product and procedures for restoring connectivity with patients.)
- Covered entity healthcare providers should evaluate the architecture, encryption and functionalities of non-public remote communication products not specifically enumerated in the OCR COVID-19 Guidance prior to utilizing such products.
The OCR COVID-19 Guidance states that covered entity healthcare providers that want to use remote communication technologies to provide telehealth to patients during the COVID-19 national emergency—even if the telehealth is not related to the diagnosis or treatment of COVID-19—can use any “non-public facing” remote communication products that are available to communicate with patients. The non-exhaustive list of such products provided by OCR includes, in the video application context, Apple FaceTime, Facebook Messenger video chat, Google Hangouts video, Whatsapp video chat and Skype, and, in the text application context, Signal, Jabber, Facebook Messenger, Google Hangouts, Whatsapp and iMessage.
The OCR COVID-19 Guidance also provides a non-exhaustive list of technologies that it considers “public-facing” and therefore not covered by the scope of its enforcement waiver. These include Facebook Live, Twitch and TikTok.
Accordingly, covered entity healthcare providers should evaluate carefully whether products that do not appear in OCR’s list of permitted examples of “non-public facing” products are actually “public” facing or “non-public” facing and whether they include security measures utilized by one or more of the specifically permitted non-public-facing products (e.g., employing end-to-end encryption, supporting individual user accounts, logins and passcodes to help limit access and verify participants, and/or permitting participants to assert some degree of control of particular capabilities, such as choosing to record or not record the communication or to mute or turn off the video or audio at any point).
Provider Operational Tips and Patient Considerations
Many patients may not have experience using remote communications products and may need guidance on how to use them as securely as possible. This is particularly important for products that have patient-facing components on patient-controlled devices (e.g., smart phones) because the security settings and practices in the patient environment may impact the assessment of the benefits and risks of using such products. Accordingly, we have included examples of additional steps that covered entities may wish to consider implementing:
- Covered entity healthcare providers should implement reasonable safeguards to prevent incidental disclosures of PHI during telehealth visits, including, for example and without limitation, adopting policies and procedures regarding provider participation in telehealth visits from private locations where the visit may not be viewed or overheard by unauthorized persons.
The HIPAA Privacy Rule provides that covered entities must reasonably safeguard PHI to limit incidental uses or disclosures of PHI made pursuant to an otherwise permitted or required use or disclosure. A commonly cited example of such incidental uses and disclosures is oral disclosures among providers in public or semi-private treatment settings (e.g., a nurses’ station). The requirement to implement reasonable safeguards to limit such disclosures continues to apply in the telehealth visit context because OCR has not expressly waived enforcement of this requirement in the OCR COVID-19 Guidance.
In fact, OCR states in the OCR FAQs 3/20/20 that providers should always use private locations and that patients should not receive telehealth services in public or semi-public settings, absent patient consent or exigent circumstances, and that, if telehealth cannot be provided in a private setting, covered entity healthcare providers should continue to implement reasonable safeguards to limit incidental uses and disclosures of PHI. Consequently, covered entity healthcare providers should implement reasonable safeguards to prevent incidental uses and disclosures of PHI during telehealth visits, including, for example and without limitation, adopting policies and procedures regarding provider participation in telehealth visits from private locations and when and whether patient consent should be obtained under exigent circumstances for telehealth visits from non-private locations. Such policies and procedures should cover, where applicable, provider participation in telehealth visits from the regular practice location, from home and semi-private locations.
- Covered entity healthcare providers should evaluate and implement processes for onboarding and engaging patients in the telehealth visit process in compliance with HIPAA and other applicable requirements. This process might include, for example and without limitation, written or oral communications to patients regarding telehealth visit scheduling, instructions for downloading relevant mobile applications, and transmissions and acknowledgements of receipt of notices of privacy practices.
Covered entity healthcare providers may face operational and communications challenges in connection with onboarding and engaging patients in the telehealth visit process. This process might include, for example and without limitation, written or oral communications to patients regarding telehealth visit scheduling, instructions for downloading relevant mobile applications, and transmissions and acknowledgements of receipt of notices of privacy practices.
To the extent such communications are transmitted via unencrypted email, OCR’s existing guidance regarding unencrypted email would likely apply. (See, for example, the OCR FAQ, “Does the HIPAA Privacy Rule permit health care providers to use e-mail to discuss health issues and treatment with their patients?”) Specifically, in accordance with this guidance, covered entity healthcare providers should evaluate the application of safeguards to reasonably protect the privacy and security of PHI transmitted via unencrypted email, including limiting the amount or type of information disclosed through unencrypted e-mail, and evaluate the need to advise patients of the risks of communication via unencrypted email. In addition, covered entity healthcare providers should ensure that any unencrypted email transmissions are otherwise in compliance with the HIPAA Privacy and Security Rules (including the rights of individuals to request methods of communication), the CAN-SPAM Act and other requirements.
To the extent such communications are transmitted to patients via SMS message or mobile device notification, covered entity healthcare providers should ensure that such transmissions comply with the HIPAA Privacy and Security Rules (including the rights of individuals to request confidential methods of communication), the Telephone Consumer Protection Act and other requirements.
The OCR COVID-19 Guidance also notes the need to explain to patients the risks and benefits of using non-HIPAA-compliant non-public-facing remote communication products. Covered entities may want to consider developing talking points to help patients appropriately balance risks to privacy against other important needs.
Healthcare providers may also want to explain to patients the steps that patients can take to safeguard their privacy if the telehealth technology involves the use of mobile device applications or other stored solutions on patient-controlled devices. For example, patients could be advised to reset passwords, improve password strength or shorten the time that a device can be idle before the device locks. If the remote communications product leverages photos (e.g., of a wound) or videos (e.g., of someone coughing or stumbling), patients could be advised about how to remove such images from their phones after the consult.
- Covered entity healthcare providers that conduct telehealth visits with more than one person in the same telehealth “session” (e.g., a healthcare provider conducts a telehealth visit with a person, the person’s spouse and/or the person’s child during the same call or video session) should ensure timely, separate and accurate documentation in each person’s EMR.
Covered entity healthcare providers should take care to timely and accurately document telehealth visits in the appropriate EMR. To the extent that providers conduct telehealth visits remotely, covered entities should evaluate the provision of remote access to applicable EMR systems in accordance with HIPAA for this purpose or otherwise ensure they have implemented policies, procedures and processes for the timely documentation of such visits. In addition, to the extent providers may visit with more than one patient during a single telehealth call or video session, providers should ensure that relevant information is documented in the record of the applicable patient to avoid potential compliance concerns and breaches of PHI.
- In addition to evaluating the HIPAA privacy and security operational considerations identified above, covered entity healthcare providers should evaluate third party payor reimbursement considerations in the telehealth context.
The enforcement waiver described in the OCR COVID-19 Guidance does not itself expand obligations of payors to reimburse for telehealth services. In fact, the OCR FAQs 3/20/20 specifically cautions providers that for purposes of reimbursement, certain payors, including Medicare and Medicaid, may impose restrictions on the type of technologies that can be used. For more information on the topic of reimbursement for telehealth during the COVID-19 national emergency, please visit the Health Law section of McDermott’s Coronavirus Resource Center.
- Covered entity healthcare providers that are substance use disorder treatment providers within the meaning of 42 C.F.R. Part 2 (Part 2) should evaluate whether more restrictive non-disclosure requirements continue to apply.
The Substance Abuse and Mental Health Services Administration (SAMHSA) provided guidance on March 19, 2020 (SAMHSA Guidance 3/19/20), in response to the COVID-19 pandemic to help ensure that substance use disorder treatment services are not interrupted by the public health emergency and acknowledging an increased need for telehealth services. The SAMHSA Guidance 3/19/20 states that Part 2’s requirements to obtain written patient consent for disclosure of substance use disorder records would not apply to utilization of telehealth services to the extent that, as determined by the provider, a medical emergency exists. This “medical emergency” exception may be narrower than the enforcement waivers described in the OCR COVID-19 Guidance, so substance use disorder treatment providers should continue to evaluate disclosures of treatment information in the Part 2 contents and whether the medical emergency exception is satisfied.
Opportunities for Additional OCR Guidance
Based on our review of the OCR COVID-19 Guidance and feedback from front-line covered entity healthcare providers, the following additional guidance from OCR could be helpful in the context of telehealth and the COVID-19 nationwide public health emergency:
- OCR could clarify that the enforcement waiver described by the OCR COVID-19 Guidance extends to failures by covered entity healthcare providers to consider non-public facing remote communication products within the scope of their HIPAA Security Rule risk analyses in connection with the good faith provision of telehealth during the COVID-19 nationwide public health emergency.
- OCR could clarify that the enforcement waiver described by the OCR COVID-19 Guidance extends to transmission of unencrypted email communications by covered entity healthcare providers to patients regarding product onboarding, telehealth visit scheduling and utilization in connection with the good faith provision of telehealth during the COVID-19 nationwide public health emergency.
- OCR could waive enforcement of the Privacy Rule requirement to provide a notice of privacy practices to patients and obtain an acknowledgement of receipt as to any covered entity healthcare provider in connection with the good faith provision of telehealth during the COVID-19 nationwide public health emergency. OCR has issued such a waiver in OCR Bulletin 3/16/20 as to “covered hospitals” under certain circumstances but not as to other types of healthcare providers. Such a waiver would expedite and streamline the provision of telehealth services, particularly as to covered entity healthcare providers and patients that do not have secure or HIPAA-compliant means of electronic transmissions of such notices or acknowledgements of receipt.

IRS Significantly Expands COVID-19 Tax Deferral Relief
ARTICLE / CLIENT ALERT
IRS Significantly Expands COVID-19 Tax Deferral Relief
March 23, 2020
Read time: 5 min
On March 20, 2020, the Internal Revenue Service expanded its relief for taxpayers in light of the Coronavirus (COVID-19) pandemic. All federal income tax payments and federal income tax returns that were due April 15, 2020, are now due July 15, 2020.
The Internal Revenue Service (IRS) announced limited relief for certain income tax payment deadlines in Notice 2020-17, dated March 18, 2020, in response to the Coronavirus (COVID-19) pandemic. On March 20, the IRS restated and expanded this relief in Notice 2020-18. The new Notice grants all taxpayers an extension of time until July 15, 2020, to make income tax payments and filings that would otherwise have been due on April 15, 2020, for the taxpayer’s 2019 taxable year as well as all first quarter estimated income tax payments for 2020.
Here are the specifics:
- All federal income tax payments and federal income tax returns that were due April 15, 2020, in respect of 2019 and all first quarter estimated income taxes that were due on April 15, 2020, are now due July 15, 2020. This extension applies to federal income tax payments and income tax returns of all taxpayers, including individuals, trusts, estates, partnerships and corporations.
- The payment deferral limits from Notice 2020-17 ($1 million for individuals and $10 million for corporations) have been removed. There is now no limitation on the amount of payment that may be postponed.
- This relief only applies to federal income tax payments (including payment of tax on self-employment income) and federal income tax returns due on April 15, 2020, with respect to the taxpayer’s 2019 taxable year, and any estimated federal income tax payments due on April 15, 2020, for the taxpayer’s 2020 taxable year. It does not apply to the second quarter estimated income tax payments that will be due on June 15, 2020.
- For purposes of calculating any interest, penalties or addition to tax for failure to file the federal income tax returns or pay the federal income taxes postponed by Notice 2020-18, the period from April 15, 2020 to July 15, 2020, will be disregarded.
- Notice 2020-18 only extends the deadlines for federal income taxes. No extension is provided for the payment or deposit of any other type of federal tax, or for the filing of any federal information return. For example, without further guidance, the April 15 deadline is not extended for the following:
- Form 709: United States Gift (and Generation-Skipping Transfer) Tax Return. Those seeking to extend the deadline to file a federal gift tax return for 2019 must complete and mail IRS Form 8892 (Application for Automatic Extension of Time to File Form 709 and/or Payment of Gift/Generation-Skipping Transfer Tax) by April 15, 2020, or IRS Form 4868 (Application for Automatic Extension of Time to File US Individual Income Tax Return) by April 15, 2020. Form 4868 automatically extends the time to file a gift tax return as well as an income tax return until October 15, 2020.
- Form 3520: Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts. Taxpayers required to file Form 3520 (or a substitute Form 3520-A required if the trustee of the taxpayer’s foreign grantor trust failed to file Form 3520-A by March 15, 2020) may seek an extension by filing IRS Form 4868 to extend their federal income tax return deadline to October 15, 2020, which will automatically extend the due date for IRS Form 3520 (and the substitute Form 3520-A).
- Form 4868. Taxpayers who want to extend the time for filing their federal income tax returns until October 15, 2020, are not relieved from filing Form 4868. This form must be filed by April 15, 2020, the regular due date of the return. The IRS likely intended to extend the time for filing Form 4868 until July 15, but it is not clear that the Notice accomplishes this.
- Report of Foreign Bank and Financial Accounts (FBAR). FBARs are due April 15, 2020, but a taxpayer who fails to timely file will automatically receive an extension to October 15, 2020.
At this time, it is unclear whether Notice 2020-18 extends installment payments due April 15, 2020, for tax liability under section 965(h). The section 965 installment obligation relates to an income tax liability assessed in a prior year, and the IRS may not view it as relating to a taxpayer’s 2019 taxable year. We are seeking more guidance on this question and will provide any updates in the future.
Notice 2020-18 only extends federal, not state or local, income tax payment and filing deadlines. Individuals and businesses may need information from their federal returns in order to complete their state filings. Some states, such as California, previously announced the delay of all tax filing and tax payments until July 15, 2020. Other states have announced that they are monitoring the situation but are not yet extending filing or payment deadlines. Some states may extend filing or payment deadlines for taxpayers without conforming to the federal extension—possibly treating individuals and businesses differently. Taxpayers should check with their state department of revenue or other state government authority to determine their filing and payment deadline. McDermott is tracking the latest state and local tax developments in response to COVID-19 in this chart.
For more information about the tax impact of the COVID-19 emergency declaration, see our recent insights.
State Tax Impacts of COVID-19
ARTICLE
State Tax Impacts of COVID-19
March 23, 2020
Read time: 1 min

Employer Concerns — New York Businesses and Nonprofits Required to Have All Employees Work From Home
ARTICLE / CLIENT ALERT
Employer Concerns — New York Businesses and Nonprofits Required to Have All Employees Work From Home
March 23, 2020
Read time: 3 min
To confront the public health crisis posed by the rapid spread of COVID-19, New York State Governor Andrew Cuomo issued three executive orders over three days. He first required a reduction of nonessential in-office workforces by 50% by March 20, 2020 (Executive Order 202.6). He then ordered a reduction by 75% by March 21, 2020 (Executive Order 202.7). Governor Cuomo finally required a reduction of in-office workforces by 100% starting March 22, 2020 at 8 pm (Executive Order 202.8). The Orders provide that businesses and nonprofits utilize, to the maximum extent possible, telecommuting or work from home procedures. The latest order is effective through April 19, 2020. Violations can result in up to a year in prison and or a fine.
As set forth in the initial order, these in-office restrictions do not apply to essential businesses, or entities providing essential services or functions, such as “banks and related financial institutions,” healthcare, utilities, grocery stores, pharmacies, sanitation, news media and “vendors that provide essential services or products, including logistics or technology support.” The latest order makes clear that entities providing essential services or functions may provide essential services to both essential businesses and nonessential businesses, and may operate to the extent necessary to provide the essential service or function. The New York State Development Corporation released guidance on determining essential businesses and entities providing essential services or functions that are not covered by the in-office restrictions. With respect to financial institutions, the guidance notes that these include banks, insurance, payroll, accounting and “services related to financial markets.”
Authored by Mark E. Brossman, Ronald E. Richman and Scott A. Gold.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.
FDA Update: FDA Enforcement Policy, Non-Invasive Remote Monitoring Devices
ARTICLE / CLIENT ALERT
FDA Update: FDA Enforcement Policy, Non-Invasive Remote Monitoring Devices
March 22, 2020
Read time: 7 min
On March 20, 2020, the US Food and Drug Administration announced updates to its enforcement policy on the use of non-invasive remote monitoring devices, specifically for uses designed to support patient monitoring during the Coronavirus (COVID-19) public health emergency. This temporary loosening of restrictions—which will be in effect only for the duration of the current emergency—is expected to increase physician access to important physiological data and facilitate patient health management without requiring in-clinic visits or in-hospital visits.
On March 20, 2020, the US Food and Drug Administration (FDA) announced its Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease-2019 (COVID-19 ) Public Health Emergency (Policy). Under the Policy, FDA intends to allow manufacturers of certain FDA-cleared non-invasive, vital sign-measuring devices to modify the technology, claims or functionality to enable remote monitoring, remote access and home use without obtaining an additional clearance for those modifications or expanded indications. FDA also clarified that it does not intend to regulate certain software applications that use established public health or clinical guidelines to help healthcare providers triage potential COVID-19 symptoms or evaluate symptom progression for patients previously diagnosed with COVID-19.
The agency’s stated goal is to “increase access to important physiological data without the need for in-clinic visits” and to “facilitate patient management by health care providers while reducing the need for in-office or in-hospital services.” FDA believes these measures will ease burdens on healthcare facilities and reduce the risk of exposure to the virus. By describing the Policy as an “enforcement policy” and identifying actions that it would not find objectionable, the agency is using its “enforcement discretion” to decline to enforce certain medical device requirements in defined circumstances.
As with other enforcement discretion policies, FDA’s criteria for non-enforcement reflects a risk-based approach. FDA policy attempts to balance the benefits of decreasing potential COVID-19 exposure through increased remote monitoring with the potential consequences of limited FDA-oversight of post-market modifications.
Non-Invasive Monitoring Devices
To qualify for enforcement discretion, the devices must (1) be non-invasive monitoring devices; (2) be previously cleared by FDA, unless they were previously 510(k)-exempt; and (3) not include any modification that creates “undue risk.” The Policy applies to the following devices:
- Clinical electronic thermometer
- Electrocardiograph (ECG)
- Cardiac monitor
- ECG software for over-the-counter use
- Pulse Oximetry (SpO2)
- Non-invasive blood pressure (NIBP)
- Respiratory rate or breathing frequency
- Electronic stethoscope
While the agency does not explicitly state that the Policy applies only to Class II, 510(k)-cleared devices, the listed examples only include Class II devices and the policy includes several references to “FDA-cleared indications.” Moreover, FDA’s description of non-enforcement focuses on modifications to functionality, technology, labeling or indications for use that typically require premarket clearance in the absence of enforcement discretion.
The third criteria for enforcement discretion—undue risk—will likely require careful consideration and calibration on the part of manufacturers. FDA states that a modification does not create undue risk in the following scenario: (1) the device is intended for the purpose of displaying, printing or analyzing the physiological parameter(s) measured by the device; (2) the device is intended for supporting or providing adjunctive (i.e., supporting) recommendations to a healthcare professional or patient about prevention, diagnosis or treatment of COVID-19 or co-existing conditions; and (3) the HCP or patient must be able to independently review the basis for any diagnostic or treatment recommendations.
FDA also provides labeling guidelines for any modified devices, including:
- A clear description of available data on the modifications, including device performance, method of determining any diagnostic or treatment recommendations, and potential risks.
- A prominent notice that recommendations are adjunctive and should not be the sole or primary basis for preventing, diagnosing or treating COVID-19 or co-existing conditions.
- Information on use conditions (e.g., whether the device is intended for spot-checking, trend monitoring or continuous monitoring).
- A statement about changes that have not been cleared by FDA and delineating
- FDA-cleared indications and claims from those that are not FDA-cleared.
- For devices previously cleared for use in a healthcare facility only, adequate instructions for use in the home setting using lay terminology.
Clinical Decision Support Software
In the Policy, FDA notes that clinical decision support (CDS) software can be useful for monitoring patients with COVID-19 or co-existing conditions. FDA emphasized that the current medical device exemptions under Section 3060(a) of the 21st Century Cures Act (Cures Act) still apply for many health-related software, including electronic health records and other categories of CDS tools that are not intended for clinical image or in vitro signal acquisition, processing analyses or diagnoses . However, FDA specifically identifies the following four examples of CDS tools for COVID-19 that are not considered medical devices:
- “Software that uses a patient’s diagnosis to provide a healthcare provider with current practice treatment guidelines for COVID-19 or co-existing conditions, and provides the source of the guidelines”
- “Software that provides healthcare providers with recommendations on the use of a medical device to treat a patient with confirmed or suspected COVID-19 that are consistent with the FDA-required labeling or that are described in other sources, such that the healthcare provider does not rely primarily on the software’s recommendation”
- “Software that compares patient signs, symptoms, or results with available practice guidelines (institutions-based or academic/clinical society-based) to recommend condition-specific diagnostic tests, investigations, or therapy or triaging patient care. The practice guidelines are described as the basis for the recommendation and provided for the health care professional to review, such that the healthcare provider does not rely primarily on the software’s recommendation”
- “A software function that is intended to analyze medical information about a patient diagnosed with COVID-19, such as temperature and heart rate, to provide recommendations to the health care professional for opportunities for additional monitoring or care, and the basis for the recommendation, such as CDC guidelines, is provided so that the health care professional does not rely primarily on the recommendation”
The key features that distinguish these non-device COVID-19 CDS examples appear to be: (1) (with one possible exception), the tools are intended for use with patients who already have a COVID-19 diagnosis; and (2) the tools are intended for healthcare provider use only. Unlike the other examples, the third example, which describes a symptom comparison and triaging tool, does not specify that such tools are only for use with previously diagnosed COVID-19 patients. The Policy describes these as examples, rather than a definitive list. Therefore, developers should analyze proposed COVID-19 CDS tools in light of the Cures Act statutory language and FDA’s previously issued guidance.
The agency reiterated the policy will only be in effect for the duration of the COVID-19 public health emergency. Manufacturers should consider proactive design protocols, notification timelines, and quality measures to reverse or terminate modifications or obtain relevant clearances for such modifications once the COVID-19 emergency has ended.
Executive and Physician Compensation, Benefits and Contract Issues in the COVID-19 Era
ARTICLE / CLIENT ALERT
Executive and Physician Compensation, Benefits and Contract Issues in the COVID-19 Era
March 22, 2020
Read time: 4 min
As the Coronavirus (COVID-19) crisis unfolds, human and economic resources are and will be strained. Hospitals and health systems must be prepared to address the executive and physician compensation, benefits and contract issues that are very likely to follow. We offer a list of such issues and considerations that can help hospitals and health systems anticipate and address current and potential challenges.
Due to the unknown severity and duration of the COVID-19 crisis, including the deepening economic slowdown, the human and financial resources of hospitals and health systems are likely to be under considerable stress. Organizations should prepare for rapid decision-making on a wide range of executive and physician employment issues, including compensation adjustments, retention arrangements, hiring decisions, and procedural changes needed to make these types of decisions with greater speed and with the possibility of a potential shortage of decision-makers.
While all organizations will need to grapple with the impact of a severe economic slowdown, hospitals and health systems will face those impacts while also being under enormous pressure to treat an expected eruption of COVID-19 patients. These are conflicting pressures, and it can be difficult to predict what the most likely challenges will be. Judging from the last economic recession, combined with the pressure to increase patient-care capacity, we believe hospitals and health systems will want to be prepared for the following types of challenges:
- Considering and preparing retention incentives and retention agreements to keep key executive leaders and key physicians in place during the crisis
- Preparing employment agreements and short-term compensation arrangements with physicians who are hired to help in the medical response crisis
- Creating a faster review and approval process for executive and physician employment and compensation decisions, if board members are not available or if time does not allow for the customary review and approval
- Creating new forms of pay for emergency, short-term physician hires
- Maintaining compensation discipline to the greatest extent possible, so that emergency compensation decisions can continue to be defended as reasonable and at fair market value, and so that they do not violate other legal standards
- Making sure incentive compensation plans and arrangements include appropriate discretion to make adjustments, change performance metrics or even suspend awards, until the crisis abates
- Adjusting or suspending supplemental executive retirement plan contributions or accruals until the crisis abates
- Changing or suspending regular employee benefit plan contributions (such as employer matching contributions to 401(k) or 403(b) plans)
- Reviewing paid time-off, leave and short-term disability programs to make sure that employees (including physicians and other direct patient caregivers) have appropriate and sufficient protection, and to make it clear when those programs apply and what they provide
- Reviewing severance benefit agreements and plans to provide the intended levels of protections and to understand the potential cost if reductions in force become necessary
- Having separation agreements and waiver and release agreements ready if reductions in force become necessary
- Navigating potential delays in hiring new employees, in implementing compensation or incentive decisions, and in other employment and pay matters
Hospitals and health systems may wish to be prepared for these types of issues as this crisis unfolds.

Families First Coronavirus Response Act Mandates Employer-Provided Coverage for COVID-19 Testing
ARTICLE / CLIENT ALERT
Families First Coronavirus Response Act Mandates Employer-Provided Coverage for COVID-19 Testing
March 20, 2020
Read time: 3 min
As part of the Families First Coronavirus Response Act (the “Act”), Congress eliminated patient cost-sharing for Coronavirus (COVID-19) diagnostic testing and related services provided under employer-sponsored group health plans. This impacts all employer plans, insured and self-funded, of all sizes. The provisions are effective as of March 18 and will continue on a temporary basis for at least 90 days unless extended by the Department Health and Human Services (HHS).
Meant to result in zero cost to consumers, the Act mandates that self-funded and fully-insured group health plans (including grandfathered plans) cover all costs (e.g., copayments, coinsurance and deductibles) related to COVID-19 diagnostic testing. This includes items and services provided during:
- Urgent care center visits,
- In-person and telehealth visits, and
- Emergency room visits that result in an order for in vitro diagnostic products approved by the Food and Drug Administration,
but only to the extent such items and services relate to the provision of the diagnostic test or the evaluation of an individual to determine whether a test is necessary. The Act additionally prohibits group health plans from imposing prior authorization or other medical management requirements on any of the foregoing COVID-19 diagnostic testing services.
Though the Act promotes early detection of COVID-19 by relieving patients of diagnostic testing costs that otherwise may have proved prohibitive, as written, its provisions place responsibility on employers for virtually unlimited costs related to COVID-19 testing. This may become particularly onerous for employers where out-of-network testing and treatment are concerned.
The Act does not extend to require coverage of treatment for COVID-19 on a first-dollar basis. However, some fully-insured plans (and other self-funded plans not subject to ERISA) are subject to state mandates that require such coverage for treatment of COVID-19 without cost-sharing to the individual. These state directives and recent guidance by the IRS (see our recent On the Subject here) have raised a number of questions for employers, including the extent to which medical care can be provided on a first-dollar basis through telemedicine for other conditions without disqualifying an individual from contributing to a health savings account. More legislation or perhaps agency guidance would be welcome on these points as employers struggle to provide care for their employees amidst the growing COVID-19 pandemic.
The Act invites the Secretaries of Health and Human Services, Labor, and Treasury to implement its provisions, and McDermott will update this article or publish new thought leadership as guidance becomes available. The Act also puts in place several measures related to employee leave and medical coverage in the face of the COVID-19 pandemic, such as expanded Family and Medical Leave Act (FMLA) and sick leave, tax credits, and certain Medicare and Medicaid coverage rules.

How to Address Beneficiary Inducement Questions During COVID-19
ARTICLE / CLIENT ALERT
How to Address Beneficiary Inducement Questions During COVID-19
March 20, 2020
Read time: 11 min
In the midst of the Coronavirus (COVID-19) pandemic, healthcare providers and suppliers will need to make decisions on how to ensure compliance with existing federal fraud and abuse laws while taking swift action to avoid disruptions in the normal delivery of care. While the US federal government has begun to issue limited guidance, there remain a number of outstanding questions. In this On The Subject, we explore scenarios and options that can help providers maintain good “compliance hygiene.”
In this unprecedented public health emergency, many healthcare providers and suppliers are facing new questions on how to address compliance with existing federal fraud and abuse laws, such as the anti-kickback statue (AKS; see 42 U.S.C. § 1320a-7b(b)) and beneficiary inducement provisions of the Civil Monetary Penalty Law (Beneficiary Inducement Statute, or BIS; see 42 U.S.C. § 1320a-7a(a)(5)), in the middle of a pandemic that requires swift action to avoid extreme disruption in the normal delivery of care.
For example, how do providers handle patients in financial need with little time to conduct a financial need assessment? How do providers find ways to deliver care to patients while protecting their workforce and those same patients during a time of social distancing that could last weeks?
The government has begun to address some of these issues. On March 17, 2020, the Department of Health and Human Services Office of Inspector General (OIG) issued a policy statement permitting routine waiver of copays for telehealth services (Policy Statement). Otherwise, there is not much precedent or guidance on applying these laws to the many ways this unusual situation is impacting the industry and beneficiaries.
However, there is some existing flexibility within these laws to address many of these questions and situations. While many of these issues are more specifically covered in BIS exceptions than under AKS safe harbors, OIG’s AKS analysis is consistently similar to its BIS analysis. Many situations may not clearly fit within a BIS exception or an AKS safe harbor, but that is not the end of the analysis. Now is the time to review the facts and circumstances and think about how common sense and reasonable mitigation steps can be applied to maintain compliance and also meet patient needs during a crisis. We address the basic framework for this analysis and the most applicable exceptions here.
Is There a Beneficiary Inducement in the First Place?
The BIS prohibits any person from paying or offering any remuneration to a Medicare or Medicaid beneficiary that the offeror knows or should know is likely to influence the beneficiary’s selection of a particular provider or supplier of Medicare- or Medicaid-payable items or services.
Existing Patients
If the patient is a long-established patient of the provider, and the remuneration is geared towards enabling the patient to continue to see that provider during a time when social distancing is recommended or mandated (such as home visits to avoid patients coming into crowded waiting areas), then there is a question about whether the BIS is truly implicated. In other words, is the remuneration being offered in a manner that the provider knows or should know is likely to influence the beneficiary’s selection of a particular provider or supplier to continue to receiving care from that provider? Or, alternatively, is the remuneration being offered to promote social distancing or another societal benefit intended to combat the spread of Coronavirus (COVID-19)?
Similarly, the AKS prohibits remuneration to induce a person, including a patient, to refer others or themselves to someone for the furnishing of items of services paid by federal healthcare programs. Again, if the patient is a long-established patient and the remuneration involved is intended to promote control of COVID-19, there is more likely to be an argument that there is no inducement triggering the AKS.
Also, keep in mind that OIG has also interpreted the BIS prohibitions to exclude offers of inexpensive items or services with a retail value of no more than $15 per item or $75 in the aggregate per patient on an annual basis. (See 81 FR 88368; prior to December 7, 2016, the limits were $10 per item or $50 in the aggregate per patient on an annual basis.) Therefore, remuneration below these thresholds generally requires no further analysis.
New Patients
As to new patients, the analysis under the BIS and AKS may become somewhat more complex, as the risks that the remuneration will be viewed as an incentive to the patient to seek care from the provider become greater. In such scenarios, providers should evaluate the arrangements from both the perspective of the provider and the perspective of the patient. For example, if the provider intends for the remuneration to motivate a new patient to seek care from the provider over another provider based on the remuneration offered, rather than based on the underlying COVID-19-related goals, the arrangement is likely to implicate both the BIS and AKS. Alternatively, if the provider is offering the remuneration with the intention to incentivize behavior that is intended to mitigate COVID-19 for all patients, both new and established, rather than to attract new patients, the risks may be lower.
For example, if the provider is implementing a new care-delivery protocol practice-wide to promote social distancing, such as offering home visits to all patients who may have greater risk of contracting the virus, then there may be an argument that there is no intent to induce the patient to seek care from that provider over another because the practice has changed the way it operates in light of the unusual circumstances posed by the pandemic.
Has the Copay or Deductible Waiver Already Been Granted by OIG?
First, we note that many diagnostic tests do not carry Medicare copays. Further, recent legislation has removed copays for COVID-19 tests. In addition, OIG’s Policy Statement notified physicians and other practitioners that they will not be subject to administrative sanctions for reducing or waiving any cost-sharing obligations federal healthcare program beneficiaries may owe for telehealth services for arrangements that satisfy both of the following conditions:
- A physician or other practitioner reduces or waives cost-sharing obligations (i.e., coinsurance and deductibles) that a beneficiary may owe for telehealth services furnished consistent with the then-applicable coverage and payment rules.
- The telehealth services are furnished during the time period subject to the COVID-19 national emergency declaration.
For any free telehealth services furnished during the time period subject to the declaration, OIG will not view the provision of free telehealth services alone to be an inducement or as likely to influence future referrals (i.e., OIG will not view the furnishing of subsequent services occurring as a result of the free telehealth services, without more, as evidence of an inducement).
OIG’s statement leaves open the more pressing question about how to enable patients who do not own the technology to conduct a telemedicine visit to receive telemedicine services when telemedicine may be the safest type of services to provide in light of COVID-19. While OIG did not go so far as to say that providing the technology to engage in telemedicine services could never be an inducement, the Policy Statement also does not say it is always an inducement. As a result, providers contemplating providing technology to patients must look for another exception or rely on a reasonable facts and circumstances analysis and risk assessment.
For other items and services, the BIS and implementing regulations contain an exception to the term “remuneration” for non-routine, unadvertised waivers of copayments or deductible amounts based on individualized determinations of financial need or exhaustion of reasonable collection efforts. Many providers have a policy on how to evaluate a patient’s financial need. In care situations that may arise due to COIVD-19, however, there may not be sufficient time to assess the patient’s financial situation under the policy. For example, a hospital may not have the time or staff to evaluate patient financial documentation in the timeframe set forth under the policy. In times of emergency, providers may need to make reasonable decisions about adjusting financial need policy requirements, such as obtaining documentation after care is provided.
Does the Remuneration Fit Within an Existing Safe Harbor?
Promoting Access to Care with Low Risk of Harm
The BIS was amended by the Affordable Care Act (ACA) to add an exception to permit “certain remuneration that poses a low risk of harm and promotes access to care” (see 81 Fed. Reg. 88396 (December 7, 2016)). OIG interprets “promoting access to care” as “improving a particular beneficiary’s, or a defined beneficiary population’s, ability to obtain items and services payable by Medicare or a State health care program.” OIG explained that its interpretation encompasses providing the tools necessary for removing “socioeconomic, educational, geographic, mobility, or other barriers that could prevent patients from seeking care (including preventive care) or following through with a treatment plan.”
OIG defines “care” in “access to care” as “access to items and services that are payable by Medicare or a state health care program for the beneficiaries who receive them.” This means that the exception may not cover remuneration that encourages beneficiaries to access services that could promote general wellness, unless those services are covered by the individual’s Medicare or state healthcare program benefit.
OIG stated that remuneration would pose a low risk of harm to Medicare and Medicaid beneficiaries and the Medicare and Medicaid programs by (i) being unlikely to interfere with, or skew, clinical decision making, (ii) being unlikely to increase costs to federal healthcare programs or beneficiaries through overutilization or inappropriate utilization and (iii) not raising patient safety or quality-of-care concerns.
For example, the temporary loan of a limited-functionality smartphone to enable an existing immunocompromised patient to receive telemedicine services during the national emergency declaration should fall within this exception.
Financial Hardship
The ACA also added a “financial hardship-based” exception to protect the offer or transfer of items or services for free or less than fair market value if (i) the item or service is not advertised or solicited, (ii) the item or service is not tied to the provision of other services reimbursed by Medicare or Medicaid, (iii) there is a reasonable connection between the item or service and the individual’s medical care, and (iv) there is an individualized determination of financial need.
OIG explained that items or services may not be “conditioned on” the patient’s use of other Medicare- or Medicaid-reimbursable services but that the item or service must be reasonably connected to an individual’s medical care from both a medical and financial perspective. Again, while this exception requires a financial-need assessment, timing exigencies unique to this pandemic may dictate conducting that assessment at a later time to avoid delays in providing needed assistance to patients to prevent bad outcomes.
Key Takeaway
In the end, providers are faced with the challenge of making reasoned judgments about how to manage the effective delivery of care in a time of crisis and with limited guidance from the government. Keep in mind that under the existing laws not all offers of remuneration to patients are prohibited. Many arrangements that providers may need to put in place to assist in controlling the spread of COVID-19 may not implicate the BIS or AKS and others may fit within a new waiver or existing safe harbor or exception.
For those arrangements that do not meet any of these exceptions, the existing “facts and circumstances” test will apply. Providers should ensure that they are taking appropriate steps to evaluate arrangements that may involve offers of remuneration to patients, but should not view the BIS and AKS as an absolute barrier to arrangements intended to benefit societal aims in “flattening the curve.”
It is important in this time to remember to maintain good “compliance hygiene” when making these decisions by creating contemporaneous documentation to explain the reasons for and intent behind the arrangement. Eventually, this crisis will end. When it does, the government or relators will inevitably raise issues for inquiry. Actions taken today to memorialize the reasons and thought that went into making these decisions will prepare you for that inquiry.